KYMERA THERAPEUTICS, INC. Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
KYMERA THERAPEUTICS, INC. (KYMR) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2026-02-26
- KYMERA THERAPEUTICS, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2024-12-31 was $0.00.
- KYMERA THERAPEUTICS, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2024-09-30 was $0.00.
- KYMERA THERAPEUTICS, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2024-06-30 was $0.00.
- KYMERA THERAPEUTICS, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2024-03-31 was $0.00, a 100.00% decline year-over-year.
- KYMERA THERAPEUTICS, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2025 was $0.00.
- KYMERA THERAPEUTICS, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- KYMERA THERAPEUTICS, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2023 was $48.83M.
- KYMERA THERAPEUTICS, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2022 was $0.00.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-02-26 | |||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $0.00 derived: sum of 2 quarters · filed 2026-02-26 | $0.00 derived: sum of 3 quarters · filed 2026-02-26 | $0.00 10-K · filed 2026-02-26 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | $0.00 derived: sum of 2 quarters · filed 2024-10-31 | $0.00 10-Q · filed 2024-10-31 | $0.00 derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $0.00 10-Q · filed 2024-08-07 | $0.00 derived: sum of 3 quarters · filed 2026-02-26 | $0.00 derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $0.00 10-Q · filed 2024-05-02 | $0.00 derived: sum of 2 quarters · filed 2026-02-26 | $0.00 derived: sum of 3 quarters · filed 2026-02-26 | $0.00 derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $0.00 derived: sum of 2 quarters · filed 2026-02-26 | $0.00 derived: sum of 3 quarters · filed 2026-02-26 | $48.83M 10-K · filed 2026-02-26 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | $0.00 derived: sum of 2 quarters · filed 2024-10-31 | $48.83M 10-Q · filed 2024-10-31 | $48.83M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $48.83M 10-Q · filed 2024-08-07 | $48.83M derived: sum of 3 quarters · filed 2025-02-27 | $48.83M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $48.83M 10-Q · filed 2024-05-02 | $48.83M derived: sum of 2 quarters · filed 2025-02-27 | $48.83M derived: sum of 3 quarters · filed 2025-02-27 | $48.83M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $0.00 derived: sum of 2 quarters · filed 2025-02-27 | $0.00 derived: sum of 3 quarters · filed 2025-02-27 | $0.00 10-K · filed 2025-02-27 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $0.00 derived: sum of 2 quarters · filed 2023-11-02 | $0.00 10-Q · filed 2023-11-02 | |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $0.00 10-Q · filed 2023-08-03 | ||
| 2022-03-31 | $0.00 10-Q · filed 2023-05-04 | |||
| 2019-12-31 | $16.32M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $16.52M 10-K · filed 2022-02-24 | ||
| 2019-09-30 | $201.00K 10-Q · filed 2020-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |